T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...